Clinical trial
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
NCT06500026
Study timeline
Study start (actual)2024-08-07Date precision: day
Registry last updated2026-04-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Small Cell Lung Cancerunresolved
Interventions
BL-B01D1DRUG
TopotecanDRUG · verified · RxNorm: topotecan
Sponsors & collaborators
Sichuan Baili Pharmaceutical Co., Ltd.lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06500026 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.